English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

In this study, we evaluated the plasma levels of endostatin (PE) and its prognostic importance in patients with acute myeloblastic (AML) and lypmhoblastic leukemia (ALL). We therefore analyzed plasma levels of endostatin before the chemotherapy and during the complete remission period in adult ALL and AML patients. The PE levels of the control group were significantly lower than both cases with ALL and AML. The patients with AML during remission had significantly higher PE levels than the levels at initial diagnosis. No statistically significant difference was detected in patients with ALL. In addition, the survival rates of the cases with ALL whose PE levels are higher than 2.5 ng/ml, are significantly lower. Our results suggest that the elevated plasma levels of endostatin during the remission in patients with AML imply the intensity of angiogenesis inhibition during the remission. Furthermore our findings in ALL patients suggest that endostatin levels may predict the overall survival of these patients.

Assessment of Plasma Endostatin Levels in Patients with Acute Myeloblastic and Lymphoblastic Leukemia